The short version: pharma is filtering out experienced commercialization talent by ZIP code while automating the desk work that geography was supposed to protect. Hire the best person for the problem, build teams around capabilities rather than locations, and bring people together deliberately when the work requires it.
There is a group of people in our industry that I think we need to talk about more.
They are experienced. Highly specialized. They have launched products, built patient-support programs, negotiated access strategies, managed GTN, designed distribution networks, led Finance organizations, worked through regulatory complexity and solved problems that sometimes take decades of experience to recognize.
Many of them are also not living within commuting distance of Boston, Cambridge, New Jersey, Philadelphia, San Francisco or one of the other traditional pharmaceutical hubs.
And increasingly, that second fact is outweighing the first.
This is not just anecdotal. In 2025, a BioSpace poll found that roughly eight in ten respondents living outside major biopharma hubs struggled to find work because of their location. In the survey covering that year's hiring plans, only 20 percent of responding employers said they would recruit and hire regardless of location.
There are signs of improvement. BioSpace's 2026 employment research found that figure had risen to 28 percent, and that 35 percent of organizations acknowledged relocation requirements cause them to miss candidates.
That number should make every pharma leader stop for a moment.
What the data says
The location filter is costing the industry people.
8 in 10
Professionals living outside major biopharma hubs who said location made finding work harder.
BioSpace, 2025
20% → 28%
Employers who say they will hire regardless of location. 2025 hiring plans versus 2026 plans.
BioSpace Employment Outlook
35%
Employers who acknowledge they miss out on candidates because of relocation requirements.
BioSpace, 2026
Full citations in the Sources and Notes below.
What Exactly Are We Optimizing For?
There are jobs in our industry that absolutely require physical presence.
You cannot manufacture a biologic from your kitchen table. You cannot run a laboratory experiment over Teams. Certain clinical, manufacturing, quality and operational activities are inherently tied to a physical environment.
But that does not describe the entire pharmaceutical enterprise.
Market Access. Patient Services. Commercial Strategy. Finance. GTN. Forecasting. Analytics. Trade and Distribution Strategy. Commercial Operations. Data Strategy. Patient Journey Design. Launch Readiness.
Many of these functions spent years proving that meaningful work could happen across geography.
And yet we seem to have arrived at an odd moment.
We are simultaneously talking about using AI, automation and RPA to perform entire workflows without a human being sitting at a desk, while telling an extraordinary human expert that we cannot hire them because their desk is in the wrong state.
There is something inconsistent about that.
Presence Is Not the Same as Engagement
Being in person does not equal being engaged. And being remote does not equal being disconnected.
I have seen both sides throughout my career.
I have seen people sitting 20 feet apart who barely understand what the other person's function does.
I have also seen teams distributed across the country come together around an important problem and accomplish more in two days than an organization accomplishes in months of standing meetings.
The difference was not geography. It was purpose.
We Have Been Asking the Wrong Question
That is the distinction I think we lost somewhere in the debate between remote and return to office.
The usual question
Where does this person work?
Optimizes for a ZIP code.
↓
The better question
When does bringing these people together create value?
Optimizes for the work.
And I am certainly not arguing against being together. Quite the opposite.
I think people are yearning for connection.
Something changed after COVID. Teams became more distributed. Relationships became more transactional. Calendars filled with video calls. Some of the informal mentorship, hallway conversations and human connection that helped many of us grow in our careers became harder to find.
Simply mandating three or four days in an office does not automatically bring that back.
Proximity is not the same thing as connection. Connection has to be designed.
Bring People Together When There Is a Reason
- Bring the commercialization team together to make a consequential launch decision.
- Bring Finance, Market Access, Patient Services and Commercial together to understand the same patient journey.
- Bring leaders together to challenge assumptions.
- Bring teams together for workshops, planning, problem-solving, mentorship and relationship building.
And when being together matters, be together. Fully. Intentionally.
Then allow people to go back and do the work.
The Knowledge Base Is Spreading. The Hiring Model Is Not.
There is another consequence we should consider.
Life sciences talent remains heavily concentrated in traditional clusters. CBRE's 2025 research continues to rank Boston-Cambridge, the San Francisco Bay Area, Washington-Baltimore and New York-New Jersey among the country's dominant R&D talent markets. But the same body of research identifies meaningful life sciences talent in places including Raleigh-Durham, Houston, Indianapolis, Denver-Boulder, Seattle, Madison and Dallas-Fort Worth.
Where the talent actually is
The knowledge base is spreading.
The hiring model often is not.
Established clusters
Boston / Cambridge
San Francisco Bay Area
Washington, D.C. / Baltimore
New York / New Jersey
Meaningful talent also in
Raleigh-Durham · Denver-Boulder · Indianapolis
Seattle · Houston · Madison · Dallas-Fort Worth
Hire the best person for the problem.
Build teams around capabilities rather than ZIP codes.
Source: CBRE, U.S. Life Sciences Talent Trends
And experienced people have moved.
They moved during COVID. They followed spouses. They wanted to raise families somewhere different. They became caregivers. They discovered different communities. Or after twenty years of building expertise, they simply decided that where they wanted to live should not determine whether they could continue contributing to an industry they love.
Some are now being asked to choose between relocating and continuing their careers. Recent cases show this is not theoretical. When EMD Serono began requiring R&D staff at its Billerica, Massachusetts institute to work on site at least three days a week, roughly 70 previously remote employees living more than 50 miles away were given three options: commute, relocate with company support, or resign with severance.
Think about what can be lost when we make that trade. Institutional knowledge. Pattern recognition. Relationships. Mentorship. Judgment. Those are not things you recreate by opening another requisition near headquarters.
The Contradiction I See From the Outside
I see this from the outside now, too.
As an advisor, I can sit with a pharmaceutical company, help solve an extraordinarily complicated commercialization problem, work alongside its executives, fly in for the moments when being together matters, and then continue the work from somewhere else.
Companies routinely accept that model from external experts. Yet sometimes they will not consider essentially the same geographic arrangement for an employee.
That contradiction is worth examining.
Expertise Without Boundaries. Presence With Purpose.
Because the future does not have to be remote versus office. There is a much more interesting model.
- Hire the best person for the problem.
- Build teams around capabilities rather than ZIP codes.
- Use technology for what technology does well.
- Use AI and automation to remove work that does not require human judgment.
- Use our offices for what people do exceptionally well together: debate, create, mentor, challenge, decide and connect.
Then bring people together deliberately at the moments that matter.
An Industry Built on Finding Rare Things
Pharma is an industry built on finding extraordinarily rare things.
Rare molecules.
Rare mechanisms.
Rare diseases.
Rare patient populations.
Perhaps we should recognize that extraordinary talent can be rare, too.
And when we find it, the first question should not be whether it lives close enough to headquarters. It should be: what could this person help us accomplish?
Talent knows no geographic boundary. Maybe our organizations should not either.
Sources and Notes
Difficulty finding work outside hubs: BioSpace, "Getting Jobs Outside of Major Biopharma Hubs Proves Tough, BioSpace Finds," February 2025.
Employer willingness to hire regardless of location: BioSpace 2026 U.S. Life Sciences Employment Outlook, reported in "Employers Warm Up to Remote Workers Again," February 2026. In a survey of 136 professionals with insight into talent acquisition or workforce planning, 28 percent said they would recruit and hire remote candidates regardless of location, up from 20 percent in the prior survey covering 2025 hiring plans and 16 percent in the survey before that. A further 52 percent who prefer local hiring said they would still consider remote hires for certain roles.
Candidates missed due to relocation requirements: Same BioSpace report. When asked whether their organization misses out on candidates because of relocation requirements, 35 percent said yes.
Talent market concentration: CBRE, U.S. Life Sciences Talent Trends 2025. Boston-Cambridge, the San Francisco Bay Area, Washington D.C.-Baltimore and New York-New Jersey remained the top-ranked U.S. clusters for life sciences R&D talent for the fourth consecutive year. CBRE analyzed the 100 largest U.S. life sciences markets; subsequent CBRE research notes gains in emerging markets including Madison and Dallas-Fort Worth, and rising venture investment in Houston, Chicago and Denver-Boulder.
EMD Serono: Reported by BioSpace, "Out of sight, out of work? What's driving remote job cuts." EMD Serono, the U.S. healthcare unit of Merck KGaA, filed a WARN Act notice regarding R&D staff reporting to its Billerica, Massachusetts research institute. Employees were required to work on site at least three days per week, and 70 remote staff living more than 50 miles away were given the option to commute, relocate with company-provided support, or resign with severance. The company cited collaboration as the reason for the requirement.
Views expressed here are my own. Nothing in this piece is legal or employment advice.
About the Author
Patrick R. Coyle is the originator of the Patients + Profitability™ philosophy and the frameworks built on it, including The 10 Exits of Therapy™ and the 5 Layers of GTN™. He previously served as VP & CFO of Eisai Americas, GTN Practice Lead at IQVIA, and Managing Director of GTN Risk Advisory at Baker Tilly, with senior finance and commercial roles at Novartis, Insmed, and Bayer. He is the Founder and CEO of Novus Proximus LLC.
More frameworks, guides, and tools in the Resource Library. Reach him at hello@patrickrcoyle.com.
The ten places a patient can leave are on the philosophy page, terms used here are defined in the glossary, and the rest of the writing is on the blog. The patient-side view of the same ten exits is at Where did your treatment stop?
The views expressed are my own and are not made on behalf of any current or former employer. All trademarks belong to their respective owners.
Free by email
The 5 Layers of GTN™, in your inbox
Gross-to-Net from someone who has run it. Tuesdays and Thursdays.
Subscribe on Substack